Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977115 | 0.92 | F2 (0.42) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL974203 | 0.91 | SLC6A9 (0.38) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL974409 | 0.91 | SLC6A9 (0.38) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL977822 | 0.89 | MEN1 (0.37) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL977322 | 0.89 | RORC (0.37) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL975274 | 0.89 | SLC6A9 (0.38) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL977045 | 0.88 | CACNA2D1 (0.41) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL975565 | 0.88 | SLC6A9 (0.36) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL976398 | 0.86 | SLC6A9 (0.38) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL976966 | 0.84 | F2 (0.35) | SLC6A9CACNA2D1CACNA1BCACNB1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | claimed |
| EP-2234966-B1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI SA (FR) | 2013-09-11 | — | — | EP | claimed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | claimed |
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI (FR) | 2013-09-12 | — | — | US | disclosed |
| US-8445478-B2 | Azetidine derivatives, their preparation and their application in therapy | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237513-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | SLC6A9 2158/4885CACNA2D1 2643/4885CACNA1B 1231/4885 |
| US-20110009377-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | QDPR, AZI2, ADRA1B | SLC6A9 2158/4885CACNA2D1 2643/4885CACNA1B 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.